Alentis Therapeutics
PrivateLast Round
Series D
Nov 12, 2024
Est. Valuation
$2B
Total Funding Raised
$365.9M
Company Overview
Alentis Therapeutics is a biotechnology company that develops innovative treatments for cancer and fibrotic diseases by targeting Claudin-1.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alentis Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Alentis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Nov 12, 2024 | ||||
| Series C | Apr 13, 2023 | ||||
| Series B | Jun 15, 2021 | ||||
| Series A | Apr 30, 2019 |
Key People
Founding team and executive leadership
Alentis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series D |
| Avego Management | Series D |
| BioMedPartners | Series A, Series B |
| RA Capital Management | Series D, Series C |
| Heartland Healthcare Capital | Series D |
| Morningside Ventures | Series B |
| Bpifrance | Series B, Series C, Series A, Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 12, 2025
Dr. Venugopal joins the executive leadership team.
- Nov 12, 2025
Mr. Yoon has joined the executive leadership team.
Alentis Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Alentis Therapeutics's valuation, stock price, and market status.